Daily FNArena News - Australia

First half results for Dulux Group were mixed and brokers are somewhat divided as the outlook lacks clarity.

Weekly update on recommendation, target price, and earnings forecast changes.

Sirtex Medical has released data from its SIRFLOX study with some statistically significant outcomes in the treatment of liver cancer.

ResMed has revealed adverse findings from its SERVE-HF trial. While limited to a specific group, brokers concede a lost growth opportunity.

FNArena’s weekly update on short positions in the Australian share market.

FNArena provides a weekly update of Australian listed corporate bond issues, current pricing and yield data.

Orica may be in a trough but several brokers hail its ability to respond to cyclical pressures, along with support from the buy-back.

Brokers hail a disciplined approach to spending and with Qantas’ transformation on track, benefits should soon flow to shareholders.

Incitec Pivot had something for every broker in its first half results but the outlook is mixed, split roughly between regions.

Super Retail is managing its headwinds reasonably well but brokers highlight the challenges in restructuring the businesses.